What is the studied dose of Bacopa Monnieri?

300–600 mg daily of a standardized extract (commonly ~50% bacosides). A studied dose is what research used, not a recommended dose.

What are the side effects of Bacopa Monnieri?

GI upset, especially on an empty stomach Occasional fatigue reported

Who should avoid Bacopa Monnieri?

Pregnant or breastfeeding without clinician guidance On thyroid medication without review

Nootropic

Bacopa Monnieri

A traditional herb standardized for compounds called bacosides. It is studied mainly for memory and learning over sustained daily use, not for same-day effects.

Evidence: Grade BSignal State Core candidateUpdated 2026-07-04Written and fact-checked in-house against The Evidence Standard — not a clinical review

Bacopa monnieri growing as a dense mat — thick, stalkless oval leaves in opposite pairs, with small pale five-lobed flowers — Photo by Vikash Kumar meena on Pexels

Educational content, not medical advice. Doses below are ranges used in research, not recommendations. Talk to a qualified clinician before starting any supplement, especially if you take medication, are pregnant, or manage a health condition.

The short answer

Bacopa Monnieri (Nootropic) is studied for memory support and learning over weeks. In our conservative reading of the published human research, the evidence is Grade B — moderate. 300–600 mg daily of a standardized extract (commonly ~50% bacosides). Typically studied over 8–12 weeks of daily use. A studied dose is what trials used, not a recommended dose.

Evidence grade: Grade B
Studied dose range: 300–600 mg daily of a standardized extract (commonly ~50% bacosides).
Time to effect: Typically studied over 8–12 weeks of daily use.
Best form: Standardized extract stating bacoside percentage.

Full profile

Also known as	Brahmi, Bacopa
Best for	Memory support · Learning over weeks · Daily cognitive routine
Evidence grade	Grade B — Moderate — several human trials, some mixed results
Studied dose range	300–600 mg daily of a standardized extract (commonly ~50% bacosides).
Time to effect	Typically studied over 8–12 weeks of daily use.
Best form	Standardized extract stating bacoside percentage.

Evidence, honestly graded

Multiple human trials over 8–12 weeks report memory and learning measures. Benefits are cumulative rather than acute.

See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.

493 licensed natural health products in Health Canada's LNHPD list Bacopa Monnieri as a medicinal ingredient.

That makes Bacopa Monnieri a recognized, licensable medicinal ingredient in Canada — regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.

Source: Health Canada Licensed Natural Health Products Database, snapshot 2026-07-26 — a count of licensed products, not an endorsement of any health claim. This describes the ingredient's regulatory standing in Canada, not Signal State Core, which is a pre-launch concept and is not a licensed natural health product.

Side effects

GI upset, especially on an empty stomach
Occasional fatigue reported

Who should avoid it or check first

Pregnant or breastfeeding without clinician guidance
On thyroid medication without review

Interactions

May interact with thyroid and sedative medications — discuss with a clinician

Stacks well with

Use caution stacking with

Additional sedating herbs without guidance

What to look for on a label

Look for the bacoside standardization percentage.
Take with food to reduce GI upset.

References

Calabrese C, Gregory WL, Leo M, et al. (2008). Journal of Alternative and Complementary Medicine, 14(6):707–713Randomized, double-blind, placebo-controlled, healthy adults 65+, 12 weeksStudied dose: 300 mg daily (≈50% bacosides)Improved delayed word recall and attention/inhibition (Stroop) versus placebo.
Morgan A, Stevens J (2010). Journal of Alternative and Complementary Medicine, 16(7):753–759Randomized, double-blind, placebo-controlled, adults 40–65, 12 weeksStudied dose: 300 mg daily standardized extractImproved verbal learning and delayed recall on the AVLT versus placebo.

Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.

Revision history

Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.

2026-07-04New profile
Initial profile published at Grade B: multiple 8–12 week human trials report memory and learning gains, with a characteristically cumulative (not acute) time course.

See how Bacopa Monnieri compares on grade, dose, and goal in the Evidence Explorer.

Related ingredients

NootropicEvidence: Emerging

Lion's Mane

An edible mushroom studied for long-term cognitive support. Human evidence is still limited, so it is positioned as an emerging ingredient with sourcing and extract-quality considerations.

Read the full breakdown

NootropicEvidence: Grade C

Huperzine-A

A plant-derived compound that strongly and selectively blocks the enzyme that breaks down acetylcholine — the same mechanism as some prescription memory drugs. That drug-like potency, thin healthy-adult evidence, and cholinergic side-effect profile make it a serious ingredient to handle carefully, not a casual add.

Read the full breakdown

NootropicGraded Out

DMAE

A small choline-related molecule marketed on the theory that it raises acetylcholine. That mechanism is poorly confirmed, healthy-adult cognition evidence is weak and dated, and animal studies show developmental-toxicity signals — so for a conservative, review-ready brand it is best understood as a flagged ingredient rather than a candidate.

Read the full breakdown

Less noise. More signal.

Get the Clean Focus Stack Guide

Join the waitlist for early access to Signal State Core and we'll send the guide — plus the ingredient research behind it. No spam, just signal.